Answers are grounded in this paper and cite their sources.
Antagonists for the ATP-gated ion channel receptor P2X1 have potential as antithrombotics and for treating hyperactive bladder and inflammation. In this study, salicylanilide derivatives were synthesized based on a screening hit. P2X1 antagonistic potency was assessed in 1321N1 astrocytoma cells stably transfected with the human P2X1 receptor by measuring inhibition of the ATP-induced calcium influx. Structure–activity relationships were analyzed, and selectivity versus other P2X receptor subtypes was assessed. The most potent compounds, N -[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide ( 1, IC 50 0.0192 μM) and N -[3,5-bis(trifluoromethyl)phenyl]-4-chloro-2-hydroxybenzamide ( 14, IC 50 0.0231 μM), displayed >500-fold selectivity versus P2X2 and P2X3, and 10-fold selectivity versus P2X4 and P2X7 receptors, and inhibited collagen-induced platelet aggregation. They behaved as negative allosteric modulators, and molecular modeling studies suggested an extracellular binding site. Besides selective P2X1 antagonists, compounds with ancillary P2X4 and/or P2X7 receptor inhibition were discovered. These compounds represent the first potent, non-acidic, allosteric P2X1 receptor antagonists reported to date.
No takes yet. Share an insight, caveat, or question.
Tian et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: